GlassScriptPhysician profile
Haley H Caire
NPI 1972185460
$3,242.81
in general payments reported to CMS, 2019-2025
14 companies · $1,751 in 2025
The $1,751 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $26.32 · 2024: $1,465 · 2025: $1,751.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,751.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,751.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $490.70 | 2025 | Skyrizi, Rinvoq |
| Genzyme Corporation | $314.47 | 2025 | |
| Ucb, INC. | $257.47 | 2025 | Bimzelx |
| Janssen Biotech, INC. | $178.13 | 2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $156.29 | 2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $68.81 | 2025 | Ebglyss |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.31 | 2025 | Spevigo |
| Incyte Corporation | $57.57 | 2025 | Opzelura |
| Pfizer INC. | $41.92 | 2025 | |
| Amgen INC. | $38.09 | 2025 | Otezla |
| Organon LLC | $27.88 | 2025 | Vtama |
| Sun Pharmaceutical Industries INC. | $25.55 | 2025 | |
| Galderma Laboratories, L.P. | $19.80 | 2025 | Nemluvio |
| Mayne Pharma Commercial LLC | $10.33 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haley Caire listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.